Trials / Terminated
TerminatedNCT00060710
CP-461 in the Treatment of Patients With Advanced Melanoma
Phase II Study of CP-461 in the Treatment of Patients With Advanced Melanoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (planned)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy of CP-461 given twice daily orally in patients with advanced or metastatic malignant melanoma and to evaluate the safety profile of CP-461 in this patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-461 |
Timeline
- Start date
- 2003-01-01
- Completion
- 2004-12-01
- First posted
- 2003-05-13
- Last updated
- 2011-10-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00060710. Inclusion in this directory is not an endorsement.